- Home
- FVNNU vs MCRB Comparison
FVNNU vs MCRB Comparison
Compare FVNNU & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FVNNU
- MCRB
- Stock Information
- Founded
- FVNNU N/A
- MCRB 2010
- Country
- FVNNU
- MCRB United States
- Employees
- FVNNU N/A
- MCRB 233
- Industry
- FVNNU
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- FVNNU
- MCRB Health Care
- Exchange
- FVNNU NYSE
- MCRB Nasdaq
- Market Cap
- FVNNU N/A
- MCRB 156.3M
- IPO Year
- FVNNU N/A
- MCRB 2015
- Fundamental
- Price
- FVNNU $10.52
- MCRB $0.92
- Analyst Decision
- FVNNU
- MCRB Buy
- Analyst Count
- FVNNU 0
- MCRB 4
- Target Price
- FVNNU N/A
- MCRB $5.63
- AVG Volume (30 Days)
- FVNNU N/A
- MCRB 2.9M
- Earning Date
- FVNNU N/A
- MCRB 11-13-2024
- Dividend Yield
- FVNNU N/A
- MCRB N/A
- EPS Growth
- FVNNU N/A
- MCRB N/A
- EPS
- FVNNU N/A
- MCRB N/A
- Revenue
- FVNNU N/A
- MCRB $126,325,000.00
- Revenue This Year
- FVNNU N/A
- MCRB N/A
- Revenue Next Year
- FVNNU N/A
- MCRB N/A
- P/E Ratio
- FVNNU N/A
- MCRB N/A
- Revenue Growth
- FVNNU N/A
- MCRB 12856.41
- 52 Week Low
- FVNNU N/A
- MCRB $0.54
- 52 Week High
- FVNNU N/A
- MCRB $2.05
- Technical
- Relative Strength Index (RSI)
- FVNNU N/A
- MCRB 57.15
- Support Level
- FVNNU N/A
- MCRB $0.85
- Resistance Level
- FVNNU N/A
- MCRB $0.97
- Average True Range (ATR)
- FVNNU 0.00
- MCRB 0.08
- MACD
- FVNNU 0.00
- MCRB 0.00
- Stochastic Oscillator
- FVNNU 0.00
- MCRB 69.85
About FVNNU FUTURE VISION II ACQUISITION CORP UNITS(1 ORD & 1/10 RT ORD)
Future Vision II Acquisition Corp is a blank check company.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.